Wednesday, August 24, 2016
Hansa Medical AB Announces top line results from Swedish ongoing phase II study with IdeS in sensitized patients presented.
Study is expected to be finalized in Q4 2016.
Results show that IdeS has enabled kidney transplantation in all 10 out of 10 included sensitized patients.
Phase II study also shows that ides treatment resulted in negative cross match test in all patients.
Source : reuters.com
